(Q33441321)

English

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma (English)

1 reference

Europe PubMed Central

4 November 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

9

object named as

M A Gertz

1 reference

Europe PubMed Central

4 November 2017

4

object named as

M Q Lacy

1 reference

Europe PubMed Central

4 November 2017

Angela Dispenzieri

1

object named as

A Dispenzieri

1 reference

Europe PubMed Central

4 November 2017

Francis K Buadi

11

object named as

F Buadi

1 reference

Europe PubMed Central

4 November 2017

6

object named as

D Dingli

1 reference

Europe PubMed Central

4 November 2017

author name string

C Tong

2

1 reference

Europe PubMed Central

4 November 2017

B LaPlant

3

1 reference

Europe PubMed Central

4 November 2017

K Laumann

5

1 reference

Europe PubMed Central

4 November 2017

Y Zhou

7

1 reference

Europe PubMed Central

4 November 2017

M J Federspiel

8

1 reference

Europe PubMed Central

4 November 2017

S Hayman

10

1 reference

Europe PubMed Central

4 November 2017

M O'Connor

12

1 reference

Europe PubMed Central

4 November 2017

V J Lowe

13

1 reference

Europe PubMed Central

4 November 2017

K-W Peng

14

1 reference

Europe PubMed Central

4 November 2017

S J Russell

15

1 reference

Europe PubMed Central

4 November 2017

publication date

25 April 2017

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

https://scigraph.springernature.com/pub.10.1038/leu.2017.120

0 references

Cancer statistics, 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Remission of disseminated cancer after systemic oncolytic virotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Trial watch: Oncolytic viruses for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Real-time PCR for mRNA quantitation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Adaptation of wild-type measles virus to CD46 receptor usage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

SLAM (CDw150) is a cellular receptor for measles virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Complement resistance of tumor cells: basal and induced mechanisms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5656536

21 June 2018

Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.120

21 January 2018

Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.120

21 January 2018

PRODUCTION OF ANTIBODIES AGAINST VIRUSES IN LEUKAEMIA AND RELATED DISEASES

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.120

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibodies to common viruses in sera from patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28439108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2017.120

1 reference

Europe PubMed Central

4 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33441321&oldid=1749479360"